RMD Related Analyst Ratings
-
Morgan Stanley Downgrades ResMed (RMD) to Equalweight
-
Jefferies & Co Downgrades ResMed (RMD) to Hold
-
Credit Suisse Upgrades ResMed (RMD) to Outperform
-
Canaccord Adams Downgrades ResMed (RMD) to Hold
-
Wachovia Downgrades ResMed (RMD) to Market Perform
-
J.P. Morgan Downgrades ResMed (RMD) to Neutral
-
Jefferies & Co Initiates Coverage on ResMed (RMD)
-
Wachovia Upgrades ResMed (RMD) to Outperform
-
Morgan Stanley Downgrades ResMed (RMD) to Underweight
-
ResMed (RMD) Could Goto $53 -Cramer
-
BMO Downgrades ResMed (RMD) to Market Perform; $41 PT
-
Piper Jaffray Starts ResMed (RMD) at Buy
-
Caris & Co Upgrades ResMed (RMD) to Buy
-
Canaccord Adams is recommending 15 names to weather a bad tape: ITRI, HOLX, HANS, ADBE, more...
-
Caris & Co Downgrades ResMed (RMD) to Above Average
-
Wachovia Downgrades ResMed (RMD) to Market Perform
-
UBS downgrades ResMed (RMD) to Neutral
-
Citigroup Initiates Coverage on ResMed (RMD) with a Hold
-
Canaccord Adams Starts ResMed (RMD) at Hold
-
BMO Capital upgrades ResMed Inc. (RMD) to Outperform
-
William Blair Defends ResMed (RMD)
-
Merrill Lynch downgrades ResMed (RMD) to Neutral
-
SunTrust Starts ResMed (RMD) at Buy
-
First Albany downgrades Resmed (RMD) to Neutral
-
Wachovia upgrades RedMed (RMD) to Outperform
-
Kaufman Brothers Starts ResMed (RMD) at Hold
-
Wachovia downgrades ResMed (RMD) to Market Perform
-
First Albany Raises Price Target on RMD
-
First Albany Raises Price Target on RMD
-
RMD upped to Outperform at Wachovia
-
RMD upped to Buy at First Albany; price tgt upped to $63/share
Back to RMD Stock Lookup
